Jixian J. Wang

Boudry, NE, Switzerland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 21 publications

Lisocabtagene maraleucel combined with ibrutinib in R/R CLL or SLL: primary results from TRANSCEND CLL 004.

Lisocabtagene maraleucel combined with ibrutinib in R/R CLL or SLL: primary results from TRANSCEND CLL 004.

Journal: Blood

Published: February 05, 2026

Bayesian dynamic power prior borrowing for augmenting a control arm for survival analysis.

Bayesian dynamic power prior borrowing for augmenting a control arm for survival analysis.

Journal: Journal of biopharmaceutical statistics

Published: June 26, 2025

Optimal dose selection in phase I/II dose finding trial with contextual bandits: a case study and practical recommendations.

Optimal dose selection in phase I/II dose finding trial with contextual bandits: a case study and practical recommendations.

Journal: Journal of biopharmaceutical statistics

Published: February 28, 2025

Quantile Effect on Duration of Response: A Zero-Inflated Censored Regression Approach.

Quantile Effect on Duration of Response: A Zero-Inflated Censored Regression Approach.

Journal: Pharmaceutical statistics

Published: January 30, 2025

Approximate Bayesian Analysis for Borrowing External Controls for Randomized Controlled Trials With Dynamic Borrowing and Covariate Balancing Adjustment.

Approximate Bayesian Analysis for Borrowing External Controls for Randomized Controlled Trials With Dynamic Borrowing and Covariate Balancing Adjustment.

Journal: Pharmaceutical statistics

Published: August 14, 2023

Adaptive designs for best treatment identification with top-two Thompson sampling and acceleration.

Adaptive designs for best treatment identification with top-two Thompson sampling and acceleration.

Journal: Pharmaceutical statistics

Published: October 29, 2022

Rejoinder: Improving the performance of Bayesian logistic regression model with overdose control in oncology dose-finding studies.

Rejoinder: Improving the performance of Bayesian logistic regression model with overdose control in oncology dose-finding studies.

Journal: Statistics in medicine

Published: August 03, 2022

Is Intention to Treat Still the Gold Standard or Should Health Technology Assessment Agencies Embrace a Broader Estimands Framework?: Insights and Perspectives From the National Institute for Health and Care Excellence and Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen on the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use E9 (R1) Addendum.

Is Intention to Treat Still the Gold Standard or Should Health Technology Assessment Agencies Embrace a Broader Estimands Framework?: Insights and Perspectives From the National Institute for Health and Care Excellence and Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen on the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use E9 (R1) Addendum.

Journal: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research

Published: February 08, 2022

Improving the performance of Bayesian logistic regression model with overdose control in oncology dose-finding studies.

Improving the performance of Bayesian logistic regression model with overdose control in oncology dose-finding studies.

Journal: Statistics in medicine

Published: May 24, 2021

Propensity score matching and stratification using multiparty data without pooling.

Propensity score matching and stratification using multiparty data without pooling.

Journal: Pharmaceutical statistics

Published: January 26, 2021

Response-adaptive trial designs with accelerated Thompson sampling.

Response-adaptive trial designs with accelerated Thompson sampling.

Journal: Pharmaceutical statistics

Published: July 21, 2020

Improved survival with enasidenib versus standard of care in relapsed/refractory acute myeloid leukemia associated with IDH2 mutations using historical data and propensity score matching analysis.

Improved survival with enasidenib versus standard of care in relapsed/refractory acute myeloid leukemia associated with IDH2 mutations using historical data and propensity score matching analysis.

Journal: Cancer medicine

Published: June 15, 2020

Showing 1-12 of 21

Last Updated: 09/26/2026